Jun 19, 2020
Full results from EMPERIAL exercise ability trials presented
May 26, 2020
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction
Mar 12, 2020
US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease
Dec 13, 2019
Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure
Nov 17, 2019
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Nov 12, 2019
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized
Aug 12, 2019
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Jun 26, 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Jun 10, 2019
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
Jun 10, 2019
New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria
Jun 04, 2019
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
Dec 12, 2018
Nationwide Program Brings Hope Home to Lung Cancer Patients During the Holidays
Nov 26, 2018
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Nov 05, 2018
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Oct 10, 2018
New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
Oct 04, 2018
Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial
Jul 19, 2018
Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint
Jun 23, 2018
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
Jun 19, 2018
Ridgefield, CT Estate with Award-Winning Gardens Scheduled for Luxury Auction® June 29th
Mar 06, 2018
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials